美国东部时间2022年05月07日上午09：33(MT Newwires)--Orchestra BioMed和Health Science Acquirements Corp.2(HSAQ)周二表示，他们已经达成合并协议。
热门资讯> 正文
Orchestra BioMed，Health Science收购公司合并；合并后的公司将在纳斯达克上市
2022-07-05 21:34
- Health Sciences Acquisitions(HSACU) 0
- HEALTH SCIENCES ACQUISITIONS CORP 2(HSAQ) 0
- Health Sciences Acquisitions(HSAC) 0
09:33 AM EDT, 07/05/2022 (MT Newswires) -- Orchestra BioMed and Health Sciences Acquisitions Corp. 2 (HSAQ) said Tuesday they have entered into a merger agreement.
The shares of the combined company -- Orchestra BioMed Holdings -- will be listed on Nasdaq under the ticker "OBIO."
合并后的公司--乐团生物医药控股公司--的股票将在纳斯达克上市，股票代码是“OBIO”。
The companies said the deal will provide a minimum of $70 million in gross proceeds to the combined company at closing and up to $160 million if there are no redemptions by Health Sciences shareholders. The combined company is expected to have a pro forma market cap of $407 million assuming no redemptions.
两家公司表示，这笔交易完成后，将为合并后的公司提供至少7000万美元的毛收入，如果Health Science的股东没有赎回，毛收入将高达1.6亿美元。假设没有赎回，合并后的公司预计预计市值将达到4.07亿美元。
Orchestra BioMed also said it has closed a $110 million Series D financing and that the combined company is expected to get a minimum of $180 million in gross proceeds from the merger and financing. The combined company is expected to have enough capital to fund operations into 2026.
Orchestra BioMed还表示，它已经完成了1.1亿美元的D系列融资，合并后的公司预计将从合并和融资中获得至少1.8亿美元的毛收入。合并后的公司预计将有足够的资本为2026年的运营提供资金。
The merger is expected to close in Q4 of 2022.
合并预计将于2022年第四季度完成。
Price: 9.99, Change: +0.01, Percent Change: +0.1
价格：9.99，变化：+0.01，变化百分比：+0.1
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
